NRx Logo
  • Our Company
  • Our Therapeutic Focus
    • Our Focus on the Brain
    • Bipolar Depression & Suicidality
    • Post-Traumatic Stress Disorder
  • Our Science
    • Our Clinical Approach
    • NRX-100/NRX-101
    • Mechanism of Action
    • NMDA & 5HT2A receptors
    • Publications & Literature
  • Pipeline
  • Investors / Media
  • Investor Relations
  • Presentation
  • Clinical Trials
  • Search

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Analyst Coverage
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Analyst Coverage
  • IR Calendar
  • Email Alerts
Mar 17, 2023 6:47am EDT

NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

Mar 09, 2023 6:47am EST

NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering

Feb 22, 2023 6:47am EST

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio

Feb 13, 2023 6:47am EST

NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

Feb 02, 2023 6:47am EST

NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior

Jan 19, 2023 6:47am EST

NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

Jan 05, 2023 6:47am EST

NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference

Jan 03, 2023 6:47am EST

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

Dec 20, 2022 1:30am EST

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Dec 05, 2022 6:47am EST

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 16
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
NRx
  • Home
  • Our Company
  • Our Science
  • Pipeline
  • News & Media
  • Resources & Patient Stories
  • Investor Relations
  • Careers
  • Contact Us
  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin
  • Forward Looking Statement
  • Privacy Policy
  • Terms of Use
  • © 2022 NRx Pharmaceuticals, Inc.

  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin